VJHemOnc is committed to improving our service to you

EHA 2019 | Upcoming updates in multiple myeloma

VJHemOnc is committed to improving our service to you

Thierry Facon

Thierry Facon, MD, of Lille University Hospital, Lille, France, discusses trial results and what the future holds for multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics
Related videos
4:41
COVID-19 in Germany
Katja Weisel
4:12
Targeting SLAMF7 in myeloma
Katja Weisel
3:04
DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma
Katja Weisel
5:17
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Katja Weisel
5:19
COVID-19: adapting to managing patients with MM
Joshua Richter
Multiple Myeloma
Carfilzomib, Daratumumab, Isatuximab
GRIFFIN
EHA 2019
Interview
14th June 2019
More from Thierry Facon
AMG 420 BiTE for R/R multiple myeloma
Monoclonal antibodies for the treatment of multiple myeloma
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals